Outcomes with bioabsorbable vascular scaffolds versus everolimus eluting stents Insights from randomized trials

International Journal of Cardiology

Volumn 212, Issue , 2016, Pages 214-222

  Bangalore, Sripal ^a   Toklu, Bora ^b   Bhatt, Deepak L ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bioresorbable scaffolds; Everolimus eluting stent; Outcomes; Thrombosis

Indexed keywords

ACUTE CORONARY SYNDROME; ARTICLE; BALLOON DILATATION; BIORESORBABLE SCAFFOLD; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DEVICE SAFETY; EVEROLIMUS ELUTING CORONARY STENT; HEART DEATH; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; STENT THROMBOSIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; AGED; BIODEGRADABLE IMPLANT; COMPARATIVE STUDY; DRUG ELUTING STENT; FEMALE; MALE; META ANALYSIS; MYOCARDIAL INFARCTION; REGRESSION ANALYSIS; STATISTICS AND NUMERICAL DATA; THROMBOSIS;

EVEROLIMUS;

ABSORBABLE IMPLANTS; AGED; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84962661772     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.03.070     Document Type: Article

References (29)

1. S. Bangalore, S. Kumar, M. Fusaro, N. Amoroso, M.J. Attubato, F. Feit, and et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials Circulation 125 2012 2873 2891
2. S. Bangalore, S. Kumar, M. Fusaro, N. Amoroso, A.J. Kirtane, R.A. Byrne, and et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials BMJ 345 2012 e5170
3. S. Bangalore, B. Toklu, N. Amoroso, M. Fusaro, S. Kumar, E.L. Hannan, and et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis BMJ 347 2013 f6625
4. K. Kolandaivelu, R. Swaminathan, W.J. Gibson, V.B. Kolachalama, K.L. Nguyen-Ehrenreich, V.L. Giddings, and et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings Circulation 123 2011 1400 1409
5. F. Otsuka, Q. Cheng, K. Yahagi, E. Acampado, A. Sheehy, S.K. Yazdani, and et al. Acute thrombogenicity of a durable polymer everolimus-eluting stent relative to contemporary drug-eluting stents with biodegradable polymer coatings assessed ex vivo in a swine shunt model JACC Cardiovasc. Interv. 8 2015 1248 1260
6. A.A. Bavry, and D.L. Bhatt Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis Lancet 371 2008 2134 2143
7. D.L. Bhatt Examination of new drug-eluting stents - top of the class! Lancet 380 2012 1453 1455
8. P. Ong, A. Athanasiadis, A. Perne, H. Mahrholdt, T. Schaufele, S. Hill, and et al. Coronary vasomotor abnormalities in patients with stable angina after successful stent implantation but without in-stent restenosis Clin. Res. Cardiol. 103 2014 11 19
9. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 ed: The Cochrane Collaboration 2008. www.cochrane-handbook.org. Accessed Dec 12, 2013.
10. D.E. Cutlip, S. Windecker, R. Mehran, A. Boam, D.J. Cohen, G.A. van Es, and et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
11. D. Moher, D.J. Cook, S. Eastwood, I. Olkin, D. Rennie, and D.F. Stroup Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement Qual. Rep. Metaanal. Lancet 354 1999 1896 1900
12. M.J. Bradburn, J.J. Deeks, and D.G. Altman Sbe24: Metan - an Alternative Meta-analysis Command Stata Technical Bulletin Reprints 8 1998 86 100
13. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control. Clin. Trials 7 1986 177 188
14. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
15. K. Thorlund, J. Engstrøm, J. Wetterslev, J. Brok, G. Imberger, and C. Gluud User Manual for Trial Sequential Analysis (TSA) (Copenhagen, Denmark: Copenhagen Trial Unit, Centre for Clinical Intervention Research) 2011 1 115
16. J. Wetterslev, K. Thorlund, J. Brok, and C. Gluud Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis J. Clin. Epidemiol. 61 2008 64 75
17. J. Wetterslev, K. Thorlund, J. Brok, and C. Gluud Estimating required information size by quantifying diversity in random-effects model meta-analyses BMC Med. Res. Methodol. 9 2009 86
18. G.D. Dangas, P.W. Serruys, D.J. Kereiakes, J. Hermiller, A. Rizvi, W. Newman, and et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) JACC Cardiovasc. Interv. 6 2013 914 922
19. G. Sarno, B. Lagerqvist, O. Frobert, J. Nilsson, O. Olivecrona, E. Omerovic, and et al. Considerably lower risk of stent thrombosis and restenosis in "new generation" drug-eluting stents: a report from the nation wide complete Swedish Coronary Angiography and Angioplasty Registry (SCAAR) (Abstract) Eur. Heart J. 32 2011 509
20. S.G. Ellis, D.J. Kereiakes, D.C. Metzger, R.P. Caputo, D.G. Rizik, P.S. Teirstein, and et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease N. Engl. J. Med. 373 2015 1905 1915
21. S.J. Hong, B.K. Kim, D.H. Shin, C.M. Nam, J.S. Kim, Y.G. Ko, and et al. Effect of intravascular ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial JAMA 1-9 2015
22. S. Cassese, R.A. Byrne, G. Ndrepepa, S. Kufner, J. Wiebe, J. Repp, and et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials Lancet 2015 (Nov 16 pii: S0140-6736(15)00979-4 doi: 101016/S0140-6736(15)00979-4)
23. R. Diletti, P.W. Serruys, V. Farooq, K. Sudhir, C. Dorange, K. Miquel-Hebert, and et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design Am. Heart J. 164 2012 654 663
24. P.W. Serruys, B. Chevalier, D. Dudek, A. Cequier, D. Carrie, A. Iniguez, and et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial Lancet 385 2015 43 54
25. R. Gao, Y. Yang, Y. Han, Y. Huo, J. Chen, B. Yu, and et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: absorb China trial J. Am. Coll. Cardiol. 2015 (Oct 6. pii: S0735-1097(15)06595-X. doi: 10.1016/j.jacc.2015.09.054)
26. T. Kimura, K. Kozuma, K. Tanabe, S. Nakamura, M. Yamane, T. Muramatsu, and et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan Eur. Heart J. 2015 (Sep 1. pii: ehv435. DOI 10.1093/eurheartj/ehv435)
27. M. Sabate, S. Windecker, A. Iniguez, L. Okkels-Jensen, A. Cequier, S. Brugaletta, and et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial Eur. Heart J. 2015 (Sep 23. pii: ehv500. DOI 10.1093/eurheartj/ehv500)
28. D. Arroyo, M. Togni, S. Puricel, B. Gerard, L. Sonja, N. Corpataux, and et al. Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial Trials 15 2014 9
29. S. Puricel, D. Arroyo, N. Corpataux, G. Baeriswyl, S. Lehmann, Z. Kallinikou, and et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds J. Am. Coll. Cardiol. 65 2015 791 801